Research ArticleClinical Investigation
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
Jasper Smit, Frank J. Borm, Anna-Larissa N. Niemeijer, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Daniela E. Oprea-Lager, Danielle J. Vugts, Guus A.M.S. van Dongen, Berlinda J. de Wit-van der Veen, Erik Thunnissen, Egbert F. Smit and Adrianus J. de Langen
Journal of Nuclear Medicine May 2022, 63 (5) 686-693; DOI: https://doi.org/10.2967/jnumed.121.262473
Jasper Smit
1Department of Thoracic Oncology, NKI-AvL, Amsterdam, The Netherlands;
2Department of Pulmonary Diseases, Leiden University Medical Centre, Leiden, The Netherlands;
Frank J. Borm
1Department of Thoracic Oncology, NKI-AvL, Amsterdam, The Netherlands;
2Department of Pulmonary Diseases, Leiden University Medical Centre, Leiden, The Netherlands;
Anna-Larissa N. Niemeijer
3Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands;
Marc C. Huisman
4Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands;
Otto S. Hoekstra
4Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands;
Ronald Boellaard
4Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands;
Daniela E. Oprea-Lager
4Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands;
Danielle J. Vugts
4Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands;
Guus A.M.S. van Dongen
4Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands;
Berlinda J. de Wit-van der Veen
5Department of Nuclear Medicine, NKI-AvL, Amsterdam, The Netherlands; and
Erik Thunnissen
6Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands
Egbert F. Smit
1Department of Thoracic Oncology, NKI-AvL, Amsterdam, The Netherlands;
Adrianus J. de Langen
1Department of Thoracic Oncology, NKI-AvL, Amsterdam, The Netherlands;

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
Jasper Smit, Frank J. Borm, Anna-Larissa N. Niemeijer, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Daniela E. Oprea-Lager, Danielle J. Vugts, Guus A.M.S. van Dongen, Berlinda J. de Wit-van der Veen, Erik Thunnissen, Egbert F. Smit, Adrianus J. de Langen
Journal of Nuclear Medicine May 2022, 63 (5) 686-693; DOI: 10.2967/jnumed.121.262473
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
Jasper Smit, Frank J. Borm, Anna-Larissa N. Niemeijer, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Daniela E. Oprea-Lager, Danielle J. Vugts, Guus A.M.S. van Dongen, Berlinda J. de Wit-van der Veen, Erik Thunnissen, Egbert F. Smit, Adrianus J. de Langen
Journal of Nuclear Medicine May 2022, 63 (5) 686-693; DOI: 10.2967/jnumed.121.262473
Jump to section
Related Articles
Cited By...
- 18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer
- Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers
- First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
- 89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer